Hsiao-Tuan Chao, M.D., Ph.D.
Associate Professor
Positions
- Associate Professor
-
Department of Pediatrics-Division of Neurology and Developmental Neuroscience, Department of Molecular and Human Genetics, Department of Neuroscience
Baylor College of Medicine
Houston, TX, US
- Investigator
-
Jan and Dan Duncan Neurological Research Institute
The Cain Pediatric Neurology Research Foundation Laboratories, Texas Children's Hospital
Houston, TX, US
- McNair Scholar
-
McNair Medical Institute at The Robert and Janice McNair Foundation
Houston, TX
- Faculty Senator
-
Baylor College of Medicine
- Associate Program Director, Basic Neuroscience Pathway
-
Department of Pediatrics
Child Neurology Residency Training Program
Baylor College of Medicine
Houston, TX, US
Addresses
- Texas Children's Hospital (Hospital)
-
Clinical Care Center, Suite 1250
Houston, TX, 77030
United States
- Jan and Dan Duncan Neurological Research Institute (Office)
-
1250 Moursund St
Houston, TX, 77030
United States
Education
- Residency at Baylor College of Medicine
- Houston, Texas, United States
- Pediatric Neurology
- Internship at Baylor College of Medicine
- 06/2013 - Houston, Texas, United States
- Pediatrics
- MD from Baylor College of Medicine
- 05/2012 - Houston, Texas, United States
- PhD from Baylor College of Medicine
- 03/2010 - Houston, Texas, United States
- Neuroscience
- BS from University of Texas at Austin
- 05/2002 - Austin, Texas, United States
- Biochemistry, summa cum laude
- BA from University of Texas at Austin
- 05/2002 - Austin, Texas, United States
- Plan II Honors in Liberal Arts, summa cum laude
Honors & Awards
- 2022 "40 Under 40" List of Autism Researchers
- Global Rising Stars in Autism Research https://www.spectrumnews.org/news/40-under-40/
- Spectrum News (12/2022)
- 2022 Young Investigator Award
- Department of Pediatrics, Baylor College of Medicine (12/2022)
- 2022 Inducted to Society for Pediatric Research
- The Society for Pediatric Research (SPR) was founded in the 1930s as an academic society committed to fostering the research and career development of investigators engaged in creating new knowledge that advances the health and well-being of children and youth. Since that time, the SPR has emerged as the pre-eminent international society devoted to young investigators in basic science and translational research. Membership is highly competitive, limited to early-stage investigators, and requires demonstration of excellence in child health research through metrics such as extramural peer-reviewed funding and publication of original scientific manuscripts.
- Society for Pediatric Research (11/2022)
- 2020 Philip R. Dodge Young Investigator Award
- https://www.bcm.edu/news/chao-awarded-philip-r-dodge-young-investigator-award
- Child Neurology Society
- 2019 Health Care Heroes - Rising Star Award
- Houston Business Journal (04/2019)
- 2017 STAT Wunderkind Award
- STAT News (10/2017)
- 2017 CNS Outstanding Junior Member Award
- Child Neurology Society
- 2017 AAN Neurology Research Scholar
- American Academy of Neurology (04/2017)
- 2017 CNCDP-K12 Scholar
- Kennedy Krieger (04/2017)
- 2011 Top 10 Autism Research Findings of 2010
- Chao et al. Nature, 2010
- Autism Speaks
- 2015-2016 Chief Resident
- 2015-2016 Co-Chief Resident with Dr. Kim Houck for Pediatric Neurology Residency Training Program
- BCM Pediatric Neurology Residency
- 2009 Deborah K. Martin Achievement Award in Biomedical Sciences
- Baylor College of Medicine
- Robert and Janice McNair Foundation MD/PhD Student Scholar
- Baylor College of Medicine (07/2002 - 05/2012)
Professional Interests
- Pathogenesis of neurodevelopmental and psychiatric disorders
- Integrate mouse and fruit fly models with human genomics
- Inhibitory neurons
- HADD syndrome
- New disease gene discovery
Professional Statement
As a physician-scientist, my efforts are primarily focused on understanding the genetic and neuro-physiologic underpinnings of neurodevelopmental disorders such as intellectual disability, epilepsy, autism, schizophrenia and other neuropsychiatric conditions. In particular, one emerging theme in the field is that disrupted inhibitory neuronal development and function has been found in association with many neurologic and psychiatric disorders. This would be consistent with the growing body of knowledge that inhibitory neurons are highly diverse and key for virtually all aspects of neurobiology from neural circuit development to information processing. Therefore, elucidating the genetic etiologies of inhibitory neuronal development and function has great potential to advance our understanding of inhibitory neurobiology in health and disease. However, determining the genetic cause is only the first step. The critical advance needed for translation of human genetic studies into clinical applications is to identify the consequences of genetic alterations at the molecular, cellular, neural network and whole-organism levels. This mechanistic dissection of neurodevelopmental disorders bridges molecular function to disease pathogenesis, which is crucial for the development of effective targeted therapeutics. Types of genetic alterations we study in the lab impact transcriptional regulation, protein translation, cell-type specific specification. synapse formation, and neurotransmitter release.
Our goal is to determine the role of cerebro-cerebellar excitatory and inhibitory neuronal dysfunction in the pathogenesis of neurodevelopmental and neuropsychiatric disorders by deciphering how genetic alterations perturb neurotransmission in the brain, impact neural development and lead to abnormal neurologic output. In the Chao Lab, we integrate cross-species approaches in humans to uncover the genetic etiologies of neurodevelopmental disorders, fruit flies to elucidate the molecular pathways and mice to explore the cascade of events in the mammalian brain and develop pre-clinical studies. A variety of approaches and techniques are employed in our laboratory including comprehensive human phenotyping and multiomics studies, genetically engineered mouse and fruit fly models, functional analyses with electrophysiology, imaging, transcriptomics, molecular and cellular assays and behavioral profiling.
In addition to the laboratory research activities, our team leads an Epilepsy Genetics Initiative at the Duncan NRI to identify genetic determinants of undiagnosed developmental and epileptic encephalopathies and we established a multidisciplinary EBF3-related autism spectrum, ataxia, and other neurodevelopmental disorders clinic at TCH. We now follow the largest group of EBF3-related HADDS and 10q26 deletion syndrome patients to date in a single institution and conduct comprehensive phenotypic-genotypic analysis with neurocognitive profiling and neuroimaging. Finally, we are leading a Phase 0 natural history study for STXBP1-related epileptic encephalopathy with the goal of continuing to Phase 1 gene therapy studies. The findings from the clinical studies also inform our laboratory research efforts to understand how gene disruptions alter inhibitory and excitatory neuronal development, perturb neural network activity and lead to cognitive and behavioral abnormalities in neurodevelopmental and psychiatric disorders.
Our goal is to determine the role of cerebro-cerebellar excitatory and inhibitory neuronal dysfunction in the pathogenesis of neurodevelopmental and neuropsychiatric disorders by deciphering how genetic alterations perturb neurotransmission in the brain, impact neural development and lead to abnormal neurologic output. In the Chao Lab, we integrate cross-species approaches in humans to uncover the genetic etiologies of neurodevelopmental disorders, fruit flies to elucidate the molecular pathways and mice to explore the cascade of events in the mammalian brain and develop pre-clinical studies. A variety of approaches and techniques are employed in our laboratory including comprehensive human phenotyping and multiomics studies, genetically engineered mouse and fruit fly models, functional analyses with electrophysiology, imaging, transcriptomics, molecular and cellular assays and behavioral profiling.
In addition to the laboratory research activities, our team leads an Epilepsy Genetics Initiative at the Duncan NRI to identify genetic determinants of undiagnosed developmental and epileptic encephalopathies and we established a multidisciplinary EBF3-related autism spectrum, ataxia, and other neurodevelopmental disorders clinic at TCH. We now follow the largest group of EBF3-related HADDS and 10q26 deletion syndrome patients to date in a single institution and conduct comprehensive phenotypic-genotypic analysis with neurocognitive profiling and neuroimaging. Finally, we are leading a Phase 0 natural history study for STXBP1-related epileptic encephalopathy with the goal of continuing to Phase 1 gene therapy studies. The findings from the clinical studies also inform our laboratory research efforts to understand how gene disruptions alter inhibitory and excitatory neuronal development, perturb neural network activity and lead to cognitive and behavioral abnormalities in neurodevelopmental and psychiatric disorders.
Websites
Chao Laboratory
Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital,
McNair Medical Institute at The Robert and Janice McNair Foundation
Chao Lab at the NRI
Jan and Dan Duncan Neurological Research Institute
Selected Publications
-
1) Corriveau ML*, Korb JC*, Michener SL, Owen NM, Wilson EL, Kubala J, Turner A, Takacs DS, Potocki L, Swann JW, Xue M, Dai H, Chao HT. " De novo chromosomes 3q and 5q chromothripsis leads to a 5q14.3 microdeletion syndrome presentation: Case report and review of the literature. " AJMG Part A. 2025 ;
Pubmed PMID: 39887826. -
2) Hayden AN, Brandel KL, Pietryk EW, Merlau PR, Vijayakumar P, Leptich EJ, Gaytan ES, Williams MI, Ni CW, Chao HT, Rosenfeld JA, Arey RN.. " Behavioral screening reveals a conserved residue in Y-Box RNA-binding protein requried for associative learning and memory in C. elegans " PLOS Genetics. 2024 ;
Pubmed PMID: 39423228. -
Saether KB, Eisfeldt J, Bengtsson J, Lun MY, Grochowski CM, Mahmoud M, Chao HT, Blieden L, Rosenfeld JA, Liu P, Schuy J, Ameur A, Undiagnosed Diseases Network, Hwang JP, Sedlazeck FJ, Bi W, Marom R, Nordgren A, Carvalho CMB, Lindstrand. " Leveraging the T2T assembly to resolve rare and pathogenic inversions in reference genome gaps " Genome Research. 2024 ;
Pubmed PMID: 39486878. -
LaFlamme CW, Tastin C, Sengupta S, Pennington HE, Russ-Hall SJ, Schneider AL,,...Chao HT...Mefford HC. " Diagnostic utility of genome-wide DNA methylation analysis in genetically unsolved developmental and epileptic encephalopathies and refinement of a CHD2 episignature. " Nat Comm. 2024 ;
Pubmed PMID: 37873138.
Projects
- Undiagnosed Epilepsy Genetics Initiative
- https://redcap.link/epilepsywgs
- Research study for patients diagnosed with epilepsy in infancy or early childhood and previous clinical genetic testing is inconclusive. If eligible, families will receive: • No charge whole-genome sequencing (WGS) or research re-analysis of clinical WGS testing. WGS is one of the most advanced genetic testing types available today • No charge fibroblast RNA-sequencing, one of the advanced genetic testing types to interpret the WGS findings
- EBF3 related disorders research study
- https://redcap.link/ebf3hadds
- Hypotonia Ataxia and Delayed Development Syndrome (HADDS) and 10q26-deletion syndrome are neurodevelopmental disorders caused by genetic changes affecting the EBF3 gene located on chromosome 10q26.3. This study aims to improve our understanding of the natural history of EBF3-related neurodevelopmental disorders and the effects on growth and development. Providers or families may visit the RedCap link to answer basic eligibility questions. A research team member will contact you.
- Chromosome 10q26 disorders research study
- https://redcap.link/10q26duplication
- 10q26-deletion and duplication syndromes are neurodevelopmental disorders caused by genetic changes affecting a region located on chromosome 10q26. This study aims to improve our understanding of the natural history of chromosome 10q26 deletion and duplication neurodevelopmental disorders and the effects on growth and development. Providers or families may visit the RedCap link to answer basic eligibility questions. A research team member will contact you.
- EIF2AK1 and EIF2AK2 related disorders research study
- https://redcap.link/eif2ak2
- LEUDEN syndrome is a neurodevelopmental and neurodegenerative disorder with leukodystrophy caused by genetic changes affecting the EIF2AK2 gene. LEMPSAD syndrome is a neurodevelopmental and neurodegenerative disorder with leukodystrophy caused by genetic changes affecting the EIF2AK1 gene. This study aims to improve our understanding of the natural history of these conditions. Providers or families may visit the RedCap link to answer basic eligibility questions. A research team member will contact you.
- STXBP1-related disorders research study
- https://redcap.link/stxbp1survey
- The STXBP1 Clinical Trial Ready (STARR), is a study focused on developing clinical trial readiness for STXBP1-related disorders, an epileptic and neurodevelopmental condition caused by changes in the STXBP1 gene. STXBP1-related disorders are one of the most common genetic causes of childhood epilepsies. Providers or families may visit the RedCap link to answer basic eligibility questions. A research team member will contact you.
- PPFIA3 related disorders research study
- https://redcap.link/ppfia3
- PPFIA3-related neurodevelopmental disorders is caused by genetic changes affecting the PPFIA3 gene. This study aims to improve our understanding of the natural history of PPFIA3-related neurodevelopmental disorders and the effects on growth and development. Providers or families may visit the RedCap link to answer basic eligibility questions. A research team member will contact you.
- A Clinical Trial of CAP-002 Gene Therapy in Pediatric Patients With Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy
- Texas Children's Hospital
- Inquiries: Contact chao-lab@bcm.edu https://www.clinicaltrials.gov/study/NCT06983158?term=NCT06983158&rank=1 A Phase 1/2a, Open-Label, Multi-Center, Dose-Escalation Trial to Assess Safety, Tolerability, and Efficacy of a Single Dose of CAP-002 Gene Therapy Administered to Pediatric Patients With Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy
Funding
-
Molecular and Cellular Mechanisms of Cerebellar Dysfunction in Neurodevelopmental disorders
#1R01NS134596 - 01A1 - (07/16/2024)
- Grant funding from NIH NINDS
-
McNair Scholar Award
- Unrestricted funding from McNair Medical Institute at The Robert and Janice McNair Foundation
-
DP5 Early Independence Award
#1DP5OD026428 - (09/17/2018)
- Grant funding from National Institutes of Health
- NIH Director's High Risk High Reward Awards Program
-
Career Award for Medical Scientists
- (01/01/2019)
- Grant funding from Burroughs Wellcome Fund
-
Undiagnosed Epilepsy Genetics
- (10/01/2020)
- Cain Pediatric Neurology Research Foundation
-
Molecular and Neural Circuit Mechanisms in Autism Spectrum Disorders
- (07/01/2021)
- Grant funding from Mark A. Wallace Endowment Award
-
EBF3-related HADDS and 10q26 deletion syndrome
- (07/01/2021)
- Gift funding from EBF3 HADDS Foundation
-
STXBP1 Clinical Trial Readiness Natural History Study (STARR)
- (07/01/2024)
- Grant funding from STXBP1 Foundation
Log In to edit your profile